176 related articles for article (PubMed ID: 29194687)
1. Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
Fiandalo MV; Wilton JH; Mantione KM; Wrzosek C; Attwood KM; Wu Y; Mohler JL
Prostate; 2018 Feb; 78(3):213-221. PubMed ID: 29194687
[TBL] [Abstract][Full Text] [Related]
2. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of proliferation and expression of AR/PSA by herbal supplement Equiguard in LNCaP cells cultured in androgen-proficient FBS and androgen-deficient charcoal-stripped FBS is correlated with increased serine-15 phosphorylation of the tumor suppressor gene p53.
Lu X; Guo J; Hsieh TC; Wu JM
Anticancer Res; 2003; 23(3B):2489-98. PubMed ID: 12894532
[TBL] [Abstract][Full Text] [Related]
4. Proteomic Analysis of Charcoal-Stripped Fetal Bovine Serum Reveals Changes in the Insulin-like Growth Factor Signaling Pathway.
Tu C; Fiandalo MV; Pop E; Stocking JJ; Azabdaftari G; Li J; Wei H; Ma D; Qu J; Mohler JL; Tang L; Wu Y
J Proteome Res; 2018 Sep; 17(9):2963-2977. PubMed ID: 30014700
[TBL] [Abstract][Full Text] [Related]
5. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
6. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
7. Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.
Tamae D; Byrns M; Marck B; Mostaghel EA; Nelson PS; Lange P; Lin D; Taplin ME; Balk S; Ellis W; True L; Vessella R; Montgomery B; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2013 Nov; 138():281-9. PubMed ID: 23851165
[TBL] [Abstract][Full Text] [Related]
8. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
9. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
10. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
12. Enhanced androgen sensitivity in serum-free medium of a subline of the LNCaP human prostate cancer cell line.
Kirschenbaum A; Ren M; Levine AC
Steroids; 1993 Sep; 58(9):439-44. PubMed ID: 8236330
[TBL] [Abstract][Full Text] [Related]
13. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.
Sedelaar JP; Isaacs JT
Prostate; 2009 Dec; 69(16):1724-9. PubMed ID: 19676093
[TBL] [Abstract][Full Text] [Related]
14. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.
Lee C; Sutkowski DM; Sensibar JA; Zelner D; Kim I; Amsel I; Shaw N; Prins GS; Kozlowski JM
Endocrinology; 1995 Feb; 136(2):796-803. PubMed ID: 7530653
[TBL] [Abstract][Full Text] [Related]
15. Neither fibroblast growth factor-1 nor fibroblast growth factor-2 is an androgen receptor coactivator in androgen-resistant prostate cancer.
Shain SA
Mol Urol; 2001; 5(3):121-30. PubMed ID: 11690559
[TBL] [Abstract][Full Text] [Related]
16. Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry.
Wilton JH; Titus MA; Efstathiou E; Fetterly GJ; Mohler JL
Prostate; 2014 May; 74(7):722-31. PubMed ID: 24847527
[TBL] [Abstract][Full Text] [Related]
17. Regulation of growth hormone receptors in human prostate cancer cell lines.
Bidosee M; Karry R; Weiss-Messer E; Barkey RJ
Mol Cell Endocrinol; 2009 Oct; 309(1-2):82-92. PubMed ID: 19540305
[TBL] [Abstract][Full Text] [Related]
18. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
19. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
Venkadakrishnan VB; DePriest AD; Kumari S; Senapati D; Ben-Salem S; Su Y; Mudduluru G; Hu Q; Cortes E; Pop E; Mohler JL; Azabdaftari G; Attwood K; Shah RB; Jamieson C; Dehm SM; Magi-Galluzzi C; Klein E; Sharifi N; Liu S; Heemers HV
Oncogene; 2019 Jun; 38(23):4496-4511. PubMed ID: 30742064
[TBL] [Abstract][Full Text] [Related]
20. Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy.
Shibata Y; Suzuki K; Arai S; Miyoshi Y; Umemoto S; Masumori N; Kamiya N; Ichikawa T; Kitagawa Y; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Kubota Y
Andrology; 2013 May; 1(3):505-11. PubMed ID: 23444052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
